SEARCH

SEARCH BY CITATION

References

  • 1
    Isaacs D, Bangham CRM, McMichael AJ. Cell-mediated cytotoxic responses to respiratory syncytial virus in infants with bronchiolitis. Lancet 1987; 2:76971.
  • 2
    Isaac D, Taylor CJ, Ting A, McMichael AJ. HLA class I antigens in severe RSV bronchiolitis. Tissue Antigens 1989; 34:2102.
  • 3
    Mbawuike IN, Wells J, Byrd R, Cron SG, Glezen WP, Piedra PA. HLA-restricted CD8+ cytotoxic T lymphocyte, interferon-γ, and interleukin-4 responses to respiratory syncytial virus infection in infants and children. J Infect Dis 2001; 183:68796.
  • 4
    McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309:137.
  • 5
    Stevenson PG, Hawke S, Bangham CRM. Protection against lethal influenza virus encephalitis by intranasally primed CD8+ memory T cells. J Immunol 1996; 157:306573.
  • 6
    Grebe KM, Yewdell JW, Bennink JR. Heterotypic immunity to influenza A virus: where do we stand? Microbes and Infect 2008; 10:10249.
  • 7
    Tripp RA, Anderson LJ. Cytotoxic T-lymphocyte precursor frequencies in BALB/C mice after acute respiratory syncytial virus (RSV) infection or immunisation with a formalin-inactivated RSV vaccine. J Virol 1998; 72:89715.
  • 8
    Hsu SC, Chargelegue D, Steward MW. Reduction of respiratory syncytial virus titer in the lung of mice after intranasal immunisation with a chimeric peptide consisting of a single CTL epitope linked to a fusion peptide. Virology 1998; 240:37681.
  • 9
    Prince GA, Mond JJ, Porter DD, Yim KC, Lan SJ, Klinman DM. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J Virol 2003; 77:1315660.
  • 10
    Carbone FR, Bevan MJ. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 1990; 171:37787.
  • 11
    Schirmbeck R, Melber K, Mertens T, Reimann J. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis. J Virol 1994; 68:141825.
  • 12
    Kast WM, Roux L, Curren J, Blom HJ, Voordouw AC, Meloen RH, Kolakofsky D, Melief CJM. Protection against lethal Sendai virus infection by in vivo priming of virus specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci USA 1991; 88:22837.
  • 13
    Hsu SC, Chargelegue D, Obeid OE, Steward MW. Synergistic effect of immunisation with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus. J Gen Virol 1999; 80:14015.
  • 14
    Oukka M, Manuguerra JC, Livaditis N, Tourdol S, Riche N, Vergnon I, Cordopatis P, Kosmatopoulos K. Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J Immunol 1996; 157:303945.
  • 15
    Stoloff GA, Caparros-Wanderley W. Synthetic multiepitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur J Immunol 2007; 37:24419.
  • 16
    Vitiello A, Yuan L, Chesnut RW et al. Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. J Immunol 1996; 157:555562.
  • 17
    Kalergis AM, Ono T, Wang F, Dilorenzo TP, Honda S, Nathenson SG. Single amino acid replacements in an antigenic peptide are sufficient to alter the TCR Vβ repertoire of the responding CD8+ cytotoxic lymphocyte population. J Immunol 1999; 162:726370.
  • 18
    Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989; 7:60124.
  • 19
    Rammensee HG, Falk K, Rőtzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993; 11:21344.
  • 20
    Engelhard VH. Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 1994; 12:181207.
  • 21
    Maryanski JL, Lűthy R, Romero P et al. The interaction of antigenic peptides with the H-2Kd MHC class I molecule. Semin Immunol 1993; 5:95104.
  • 22
    Quesnel A, Hsu SC, Delmas A, Steward MW, Trudelle Y, Abastado JP. Efficient binding to the MHC class I Kd molecule of synthetic peptides in which the anchoring position 2 does not fit the consensus motif. FEBS Lett 1996; 387:426.
  • 23
    Guichard G, Calbo S, Muller S, Kourilsky P, Briand JP, Abastado JP. Efficient binding of reduced peptide bond pseudopeptides to major histocompatibility complex class I molecule. J Biol Chem 1995; 270:260579.
  • 24
    Silver ML, Guo H-C, Strominger JL, Wiley DC. Atomic structure of a human MHC molecule presenting an influenza virus peptide. Nature 1992; 360:3679.
  • 25
    Zhang W, Young AC, Imarai M, Nathenson SG, Sacchettinni JC. Crystal structure of the major histocompatibility complex class I H-2Kb molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition. Proc Natl Acad Sci USA 1992; 89:84037.
  • 26
    Romero P, Casanova JL, Cerottini JC, Maryanski JL, Luescher IF. Differential T cell receptor photoaffinity labeling among H-2Kd-restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative. Labelling of the α-chain correlates with Jα Segment Usage. J Exp Med 1993; 177:124756.
  • 27
    Wan J, Liu W, Xu Q, Ren Y, Flower DR, Li T. SVRMHC prediction server for MHC-binding peptides. BMC Bioinformatics 2006; 7:463.
  • 28
    Doytchinova IA, Guan P, Flower DR. EpiJen: a server for multistep T cell epitope prediction. BMC informatics 2006; 7:131.
  • 29
    Larsen MV, Lundegaard C, Lamberth K, Buus S, Brunak S, Lund O, Nielsen M. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency and proteasomal cleavage predictions. Eur J Immunol 2005; 35:2295303.
  • 30
    Doytchinova IA, Flower DR. Predicting class I major histocompatibility complex (MHC) binders using multivariate statistics: comparison of discriminant analysis and multiple linear regression. J Chem Inf Model 2007; 47:2348.
  • 31
    Doytchinova IA, Flower DR. Modeling the peptide-T cell receptor interaction by the comparative molecular similarity indices analysis – soft independent modeling of class analogy technique. J Med Chem 2006; 49:21939.
  • 32
    Jojic N, Reyes-Gomez M, Heckerman D, Kadie C, Schueler-Furman O. Learning MHC 1-peptide binding. Bioinformatics 2006; 22:e227.
  • 33
    Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:2139.
  • 34
    Singh H, Raghava GPS. ProPred I: prediction of promiscuous MHC class-I binding sites. Bioinformatics 2003; 19:100914.
  • 35
    Altuvia Y, Sette A, Sidney J, Southwood S, Marglit H. A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets. Hum Immunol 1997; 58:111.
  • 36
    Chen YC, Lo YS, Hsu WC, Yang JM. 3D-partner: a web server to infer interacting partners and binding models. Nucleic Acids Res 2007; 35:W5617.
  • 37
    Townsend A, Ohlën C, Foster L, Bastin J, Ljunggren HG, Kärre K. Mutant cell in which association of class I heavy and light chains is induced by viral peptides. Cold Spring Harb Symp Quant Biol 1989; 1:299308.
  • 38
    Chen W, Yewdell JW, Levine RL, Bennink JR. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J Exp Med 1999; 189:175764.
  • 39
    Smith W, Andrewes CH, Laidlaw PP. A virus obtained from influenza patients. Lancet 1933; 1:668.
  • 40
    Kos FJ, Müllbacher A. Enhancement of antigen-specific activation of CD8+ memory cytotoxic T cells by B cell-derived factors. Immunobiology 1992; 186:41020.
  • 41
    Kos FJ, Müllbacher A. Specific epitope-induced conversion of CD8+ memory cells into effector cytotoxic T lymphocytes in vitro: presentation of peptide antigens by CD8+ T cells. Eur J Immunol 1992; 22:1595601.
  • 42
    Lo YS, Lin CY, Yang JM. PC family: a web server for searching homologous protein complexes. Nucleic Acids Res 2010; 38:W51622.
  • 43
    Kulkarni AB, Morse HC III, Bennink JR, Yewdell JW, Murphy BR. Immunisation of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells. J Virol 1993; 67:408692.
  • 44
    DiBrino M, Tsuchida T, Turner RV, Parker KC, Coligan JE, Biddison WE. HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs. J Immunol 1993; 151:59305.
  • 45
    Sadovnikova E, Zhu X, Collins SM, Zhou J, Vousden K, Crawford L, Beverley P, Stauss HJ. Limitation of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papillomavirus E7 protein. Int Immunol 1994; 6:28996.
  • 46
    Jiang S, Borthwick NJ, Morrison P, Gao GF, Steward MW. Virus-specific CTL responses induced by an H-2Kd-restricted motif-negative 15-mer peptide from the fusion protein of respiratory syncytial virus. J Gen Virol 2002; 83:42938.
  • 47
    Holtappels R, Simon CO, Munks MW et al. Subdominant CD8 T cell epitopes account for protection against cytomegalovirus independent of immunodomination. J Virol 2008; 82:578196.
  • 48
    Van der Most RG, Sette A, Oseroff C et al. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol 1996; 157:554354.
  • 49
    Guda C, Lu S, Scheeff ED, Bourne PE, Shindyalov LN. CE-MC: a multiple protein structure alignment server. Nucleic Acids Res 2004; 32:W1003.
  • 50
    Reiser J-B, Darnault C, Grégoire C et al. CDR3 loop flexibility contributes to the degeneracy of TCR recognition. Nat Immunol 2003; 4:2417.
  • 51
    Hall CB, Weinberg GA, Iwane MK et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360:58874.
  • 52
    Chowell G, Bertozzi SM, Colchero MA, Gatell HL, Alpuche-Aranda C, Hernandez M. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009; 361:6749.
  • 53
    Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunisation. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89:43548.
  • 54
    Srikiatkhachorn A, Braciale TJ. Virus-specific CD8+ T lymphcoytes downregulate T helper cell type 2 cytokine seretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 1997; 186:42132.
  • 55
    Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006; 24:41966.
  • 56
    Reiser J-B, Darnault C, Guimezanes A et al. Crystal structure of a T cell receptor bound to an allogeneic MHC molecule. Nat Immunol 2000; 1:2917.
  • 57
    Reiser J-B, Grégoire C, Darnault C et al. T cell receptor CDR3β loop undergoes conformational changes of unprecedented magnitude upon binding to a peptide/MHC class I complex. Immunity 2002; 16:34554.
  • 58
    Ker-Nielsen L, Clements CS, Purcell AW, Brooks AG, Whisstock JC, Burrows SR, McCluskey J, Rossjohn J. A structural basis for the selection of dominant αβ T cell receptors in antiviral immunity. Immunity 2003; 18:5364.
  • 59
    Tynan FE, Burrows SR, Buckle AM et al. T cell receptor recognition of a ‘super-bulged’ major histocompatibility complex class I-bound peptide. Nat Immunol 2005; 6:111422.
  • 60
    Garcia KC, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PA, Teyton L, Wilson IA. An αβ T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. Science 1996; 274:20919.
  • 61
    Stewart-Jones GBE, McMichael AJ, Bell JI, Stuart DI, Jones Y. A structural basis for immunodominant human T cell receptor recognition. Nat Immunol 2003; 4:65763.
  • 62
    Lee JK, Stewart-Jones G, Dong T et al. T cell cross-reactivity and conformational changes during TCR engagement. J Exp Med 2004; 200:145586.
  • 63
    Theodossis A, Guillonneau C, Welland A et al. Constraints within major histocompatibility complex class I restricted peptides: presentation and consequences for T cell recognition. Proc Natl Acad Sci USA 2010; 107:55349.
  • 64
    Ding Y-H, Baker BM, Garboczi DN, Biddison WE, Wiley DC. Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity 1999; 11:4556.
  • 65
    Baker MB, Gagnon SJ, Biddison WE, Wiley DC. Conversion of a T cell antagonist into agonist by repairing a defect in the TCR/peptide/MHC interface: implications for TCR signaling. Immunity 2000; 13:47584.
  • 66
    Yang JM, Tsai CH, Hwang MJ, Tsai HK, Hwang JK, Kao CY. GEM: a Gaussian evolutionary method for predicting protein side-chain conformations. Protein Sci 2002; 11:1897907.
  • 67
    Zhao X, Sullender WM. In vivo selection of respiratory syncytial virus resistant to palivizumab. J Virol 2005; 79:39628.
  • 68
    Voeten JTM, Bestebroer TM, Nieuwkoop NJ, Fouchier RAM, Osterhaus ADME, Rimmelzwaan GF. Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol 2000; 74:68007.
  • 69
    Berkhoff EGM, de Wit E, Geelhoed-Mieras MM, Boon ACM, Symons J, Fouchier RAM, Osterhaus ADME, Rimmelzwaan GF. Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes. J Virol 2005; 79:1123946.
  • 70
    Boon ACM, de Mutsert G, Graus YMF, Fouchier RAM, Sintnicolaas K, Osterhaus ADME, Rimmelzwaan GF. Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. J Virol 2002; 76:256772.
  • 71
    Uhlin M, Masucci M, Levitsky V. Is the activity of partially agonistic MHC: peptide ligands dependent on the quality of immunological help? Scan J Immunol 2006; 64:5817.
  • 72
    Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 1998; 394:4825.
  • 73
    Anderson R, Huang Y, Langley JM. Prospects for defined epitope vaccines for respiratory syncytial virus. Future Med 2010; 4:585602.
  • 74
    Sparer TE, Matthews S, Hussell T, Rae AJ, Garcia-Barreno B, Melero JA, Openshaw PJM. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J Exp Med 1998; 187:19216.
  • 75
    Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001; 20:6375.